Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Dipeptidyl‐peptidase (DPP)‐4 Inhibitors and Glucagon‐like Peptide (GLP)‐1 Analogues for Prevention or Delay of Type 2 Diabetes Mellitus and Its Associated Complications in People at Increased Risk for the Development of Type 2 Diabetes Mellitus." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/439117/all/Dipeptidyl‐peptidase__DPP_‐4_inhibitors_and_glucagon‐like_peptide__GLP_‐1_analogues_for_prevention_or_delay_of_type_2_diabetes_mellitus_and_its_associated_complications_in_people_at_increased_risk_for_the_development_of_type_2_diabetes_mellitus_New. Accessed 20 April 2024.
Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/439117/all/Dipeptidyl‐peptidase__DPP_‐4_inhibitors_and_glucagon‐like_peptide__GLP_‐1_analogues_for_prevention_or_delay_of_type_2_diabetes_mellitus_and_its_associated_complications_in_people_at_increased_risk_for_the_development_of_type_2_diabetes_mellitus_New. Accessed April 20, 2024.
Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/439117/all/Dipeptidyl‐peptidase__DPP_‐4_inhibitors_and_glucagon‐like_peptide__GLP_‐1_analogues_for_prevention_or_delay_of_type_2_diabetes_mellitus_and_its_associated_complications_in_people_at_increased_risk_for_the_development_of_type_2_diabetes_mellitus_New
Dipeptidyl‐peptidase (DPP)‐4 Inhibitors and Glucagon‐like Peptide (GLP)‐1 Analogues for Prevention or Delay of Type 2 Diabetes Mellitus and Its Associated Complications in People at Increased Risk for the Development of Type 2 Diabetes Mellitus [Internet]. In: Cochrane Abstracts. [cited 2024 April 20]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/439117/all/Dipeptidyl‐peptidase__DPP_‐4_inhibitors_and_glucagon‐like_peptide__GLP_‐1_analogues_for_prevention_or_delay_of_type_2_diabetes_mellitus_and_its_associated_complications_in_people_at_increased_risk_for_the_development_of_type_2_diabetes_mellitus_New.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus
ID - 439117
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/439117/all/Dipeptidyl‐peptidase__DPP_‐4_inhibitors_and_glucagon‐like_peptide__GLP_‐1_analogues_for_prevention_or_delay_of_type_2_diabetes_mellitus_and_its_associated_complications_in_people_at_increased_risk_for_the_development_of_type_2_diabetes_mellitus_New
DB - Evidence Central
DP - Unbound Medicine
ER -